Enzon Pharmaceuticals, Inc. (BST:EZ1)
Germany
· Delayed Price · Currency is EUR 0.0270
0.00 (0.00%)
At close: Dec 5, 2025
Enzon Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 43.26 | 46.86 | 47.01 | 46.98 | 47.64 | 48.14 | Upgrade
|
| Cash & Short-Term Investments | 43.26 | 46.86 | 47.01 | 46.98 | 47.64 | 48.14 | Upgrade
|
| Cash Growth | -7.24% | -0.33% | 0.06% | -1.38% | -1.04% | 783.99% | Upgrade
|
| Accounts Receivable | - | - | - | - | 0.03 | 0.03 | Upgrade
|
| Receivables | - | - | - | - | 0.03 | 0.03 | Upgrade
|
| Other Current Assets | 0.41 | 0.29 | 0.33 | 0.41 | 0.09 | 0.06 | Upgrade
|
| Total Current Assets | 43.67 | 47.15 | 47.34 | 47.39 | 47.75 | 48.23 | Upgrade
|
| Long-Term Deferred Tax Assets | 0.03 | 0.02 | 0.36 | 0.2 | - | - | Upgrade
|
| Total Assets | 43.69 | 47.17 | 47.7 | 47.59 | 47.75 | 48.23 | Upgrade
|
| Accounts Payable | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.3 | Upgrade
|
| Accrued Expenses | 0.07 | 0.07 | 0.09 | 0.09 | 0.06 | 0.09 | Upgrade
|
| Other Current Liabilities | 0.14 | 1.28 | 1.29 | 1.28 | 0.01 | 0.02 | Upgrade
|
| Total Current Liabilities | 0.54 | 1.68 | 1.71 | 1.7 | 0.4 | 0.41 | Upgrade
|
| Total Liabilities | 0.54 | 1.68 | 1.71 | 1.7 | 0.4 | 0.41 | Upgrade
|
| Common Stock | 0.74 | 0.74 | 0.74 | 0.74 | 0.74 | 0.74 | Upgrade
|
| Additional Paid-In Capital | 70.57 | 72.16 | 73.43 | 74.71 | 75.98 | 78.01 | Upgrade
|
| Retained Earnings | -72.23 | -69.89 | -70.67 | -72.04 | -71.86 | -71.39 | Upgrade
|
| Total Common Equity | -0.92 | 3.01 | 3.51 | 3.41 | 4.87 | 7.36 | Upgrade
|
| Shareholders' Equity | 43.15 | 45.49 | 45.99 | 45.89 | 47.35 | 47.82 | Upgrade
|
| Total Liabilities & Equity | 43.69 | 47.17 | 47.7 | 47.59 | 47.75 | 48.23 | Upgrade
|
| Net Cash (Debt) | 43.26 | 46.86 | 47.01 | 46.98 | 47.64 | 48.14 | Upgrade
|
| Net Cash Growth | -7.24% | -0.33% | 0.06% | -1.38% | -1.04% | 783.99% | Upgrade
|
| Net Cash Per Share | 0.58 | 0.63 | 0.63 | 0.63 | 0.64 | 0.94 | Upgrade
|
| Filing Date Shares Outstanding | 74.21 | 74.21 | 74.21 | 74.21 | 74.21 | 74.21 | Upgrade
|
| Total Common Shares Outstanding | 74.21 | 74.21 | 74.21 | 74.21 | 74.21 | 74.21 | Upgrade
|
| Working Capital | 43.13 | 45.47 | 45.63 | 45.69 | 47.35 | 47.82 | Upgrade
|
| Book Value Per Share | -0.01 | 0.04 | 0.05 | 0.05 | 0.07 | 0.10 | Upgrade
|
| Tangible Book Value | -0.92 | 3.01 | 3.51 | 3.41 | 4.87 | 7.36 | Upgrade
|
| Tangible Book Value Per Share | -0.01 | 0.04 | 0.05 | 0.05 | 0.07 | 0.10 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.